According to research report titled ‘Atrial Fibrillation Drugs Market Size By Products (Antiarrhythmic Drugs, Anticoagulant Drugs {Vitamin K Antagonists, Novel Oral Anticoagulants [Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors]}), By Atrial Fibrillation Type (Paroxysmal, Persistent, Permanent), By Application (Heart Rhythm Control, Heart Rate Control) By Route of Administration (Oral, Injectable) By End-use (Hospitals, Cardiac Centres, Ambulatory Surgical Centres) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Poland, Switzerland, Belgium, Czech Republic, Netherlands, Sweden, Hungary, Austria, Portugal, Denmark, Norway, Finland, Ireland, Turkey, Greece, China, Japan, India, Australia, South Korea, Taiwan, New Zealand, Singapore, Brazil, Argentina, Venezuela, Columbia, Mexico, South Africa, Saudi Arabia, UAE, Egypt), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025’, available with MarketStudyReport, atrial fibrillation drugs market is anticipated to surpass a valuation of USD 17 billion by the year 2025.

As per credible estimates, ever-increasing elderly population around the world, and rising prevalence of valvular illnesses are the major growth determinants for global atrial fibrillation drugs market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/2057027/

Furthermore, extensive adoption of sedentary lifestyle, in consort with an increasing habit of binge eating among millennials in both developed and developing countries are expected to impel industry trends in the approaching years.

However, side effect of drugs, such as severe bleeding, fatigue, among others, as well as inadequate knowledge of modern medical medication regimens for the treatment of atrial fibrillation may stymie market expansion during 2019-2025.

Based on product terrain, the anticoagulant drugs segment is slated to record a CAGR of 3.5% over the estimated timeframe, due to demand for these medications to be used in all three stages of atrial fibrillation as well as ability to reduce the rate of stroke in people suffering from the said disease.

In terms of atrial fibrillation type, the paroxysmal segment of atrial fibrillation drugs market was worth USD 7,095.8 million in 2018 and is anticipated to grow significantly through 2025, owing to rising proportion of baby boomers, as well as an increasing number of patients suffering from this condition.

On the basis of route of administration, injectable segment is expected to increase at a rate of 2.4% over the stipulated timeframe, due to its widespread use in patients with acute atrial fibrillation who are unable to take medications orally.

Speaking of end-use scope, the hospital segment was worth USD 6583.2 million in 2018 and is poised to witness robust growth during 2019-2025, owing to increasing popularity of this setting in developed nations, and rising drug supply agreements between manufacturers and hospitals.

Regionally, the U.S. market is touted to progress with 2.4% CAGR over the analysis timeframe, on account of growing number of significant participants, and increasing prevalence of chronic conditions such as hypertension, diabetes, among others in the country.

The key players in global atrial fibrillation drugs industry are Sanofi S.A., Portola Pharmaceuticals, Inc., Pfizer, Inc., Mitsubishi Tanabe Pharma Corporation, Johnson and Johnson, GlaxoSmithKline plc, Daiichi Sankyo Co., Ltd., Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, and AstraZeneca plc.